Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LSS | P48449 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604119 | 0.86 | CA1 (0.44) | SMN1; SMN2LSSALDH1A1NSD2HTT | |
| SCHEMBL13612192 | 0.85 | CA1 (0.40) | SMN1; SMN2ALDH1A1NSD2HTTNPSR1 | |
| SCHEMBL13611592 | 0.85 | TP53 (0.40) | SMN1; SMN2ALDH1A1NSD2HTTNPSR1 | |
| SCHEMBL8288305 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2LSSALDH1A1NSD2HTT | |
| SCHEMBL13612184 | 0.83 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1HTTNPSR1KMT2A | |
| SCHEMBL13611590 | 0.81 | ALDH1A1 (0.40) | LSSALDH1A1KMT2A | |
| SCHEMBL13612187 | 0.76 | ALDH1A1 (0.42) | ALDH1A1KMT2A | |
| SCHEMBL10282788 | 0.71 | LPL (0.40) | CA1CA2CA9 | |
| SCHEMBL13604132 | 0.70 | LPL (0.47) | ALDH1A1NSD2HTTNPSR1KMT2A | |
| SCHEMBL13604122 | 0.70 | LPL (0.47) | ALDH1A1HTTNPSR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | SMN1; SMN2 4724/4885LSS 1830/4885ALDH1A1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.